Search

Your search keyword '"Epelbaum, Ron"' showing total 223 results

Search Constraints

Start Over You searched for: Author "Epelbaum, Ron" Remove constraint Author: "Epelbaum, Ron"
223 results on '"Epelbaum, Ron"'

Search Results

1. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

4. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients

20. The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study

21. Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

23. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas

25. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables

26. Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.

28. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer

30. RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

31. Mutant <italic>KRAS</italic> Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

32. Program for the Fifth Rambam Research Day

34. Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation

36. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study

37. Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

38. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/ CT is beneficial: a prospective multicentre trial of 355 patients.

39. A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.

42. Primary breast lymphoma : patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

43. Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study

49. Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

50. A 10-year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved

Catalog

Books, media, physical & digital resources